GAP feasibility trial completed

The GAP feasibility study demonstrated that ward-based, non-invasive goal-directed fluid therapy is acceptable and deliverable in patients with acute pancreatitis, with signals of reduced systemic inflammation, shorter hospital stay and less progression to severe disease. These findings directly informed the Stage 2 design.